Natco pharma q3 results 2025: After Natco Pharma’s poor Q3 earnings performance, investors sold the stock, which causes the shares of Natco Pharma to go as down as 18.5% in trading on February 13.
The pharmaceutical company’s net profit for the most recent quarter fell 38 percent year-over-year to Rs 132.4 crore in Q3, a significant decrease from the Rs 212.7 crore it earned during the same period in the previous fiscal year. Revenue also decreased by more than 37% to Rs 474.8 crore in Q3 from Rs 758.6 crore in the same quarter last year.
Natco pharma q3 results 2025 expected
The EBITDA margin declines by an astounding 2,717 basis points to 8.2 percent in the December quarter from 35.3 percent in the same time of the previous year, operational performance also drastically deteriorated.
ALSO READ:
https://samacharpatrika24.com/nalco-share-price/
A significant contributor to Natco Pharma’s overall profitability was the precipitous drop in its formulation exports, which fell more than half to Rs 285.8 crore in Q3 from Rs 605.6 crore in the base period. Additionally, sales of domestic formulations also declined, down from Rs 99.4 crore to Rs 96.1 crore just a year ago. Natco pharma q3 results 2025
Natco Pharma’s Q3 performance was not satisfactory. A 38% YoY profit decline and a 37% revenue drop are bad enough, but that EBITDA margin collapse (from 35.3% to 8.2%) is shocking. The sharp fall in formulation exports is the biggest red flag—losing more than half in a year suggests serious competitive or regulatory challenges.With the stock tanking 18.5% in response, it seems the market wasn’t expecting such a poor showing. Do you think this is a temporary setback, or is Natco facing a deeper structural issue? Natco pharma q3 results 2025
(Disclaimer:Not a buying/selling recommendation. Do your own research or ask your financial advisor for any trade.)
